Clinical and Economic Outcomes of Transcutaneous Afferent Patterned Stimulation for Essential Tremor
Journal of Health Economics and Outcomes Research · 22.10.2026 · 13 (2)
DOI: 10.36469/001c.170793 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Health Economics and Outcomes Research, online erschienen am 22.10.2026. Verfasst von Dingwei Dai und 3 weiteren Autor:innen. Beteiligte Einrichtung: CVS Healthspire™ Life Sciences Solution, Woonsocket, Rhode Island, USA. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
TAPS® therapy (Cala Health) delivers transcutaneous afferent patterned stimulation through a noninvasive, wrist-worn neuromodulation device for the treatment of hand tremor in patients with essential tremor (ET). Although previous studies have demonstrated its effectiveness and safety, real-world evidence regarding its long-term clinical outcomes and economic impact remains limited.
Objectives
To evaluate the long-term clinical effectiveness and the healthcare resource utilization and cost impact of TAPS in patients with ET treated in real-world settings.
Methods
Patients who completed a 1-month randomized pragmatic phase comparing TAPS with standard of care entered 12 months of open-label home use. Clinical outcomes were assessed via device-based motion sensors and the Bain & Findley Activities of Daily Living (BF-ADL) upper-limb scale at baseline and every 3 months. Healthcare resource utilization and costs over the 12-month TAPS treatment period were compared with those during the 12 months before TAPS initiation and with a propensity-score-matched external control arm (ECA) derived from a large US commercial and Medicare Advantage claims database.
Results
Among 225 patients who used TAPS therapy for 12 months, daily functioning improved, with the mean BF-ADL score decreasing from 17.2 to 15.8 ( P < .003). Device-measured tremor power decreased by more than 50% ( P < .001). No serious device-related adverse events were reported. In the ECA analysis, 153 TAPS-treated patients were matched to 306 ECA patients. Compared with baseline, TAPS-treated patients experienced significant reductions in ET-related healthcare costs ($440 decrease; P < .0001), ET-related medication use (15% fewer patients; P < .01), and ambulatory and office visits (~0.3 fewer each; P < .05). These reductions were significantly greater than those observed in the ECA (all P < .05).
Discussion
This is the largest and longest prospective ET study to jointly assess tremor severity, daily function, and healthcare economic outcomes. The sustained clinical benefits observed with TAPS therapy, together with reductions in ET-related healthcare utilization and costs, support TAPS as a noninvasive treatment option for adults with ET.
Conclusions
Over 12 months of real-world use, TAPS reduced tremor severity, improved daily functioning, and lowered ET-related healthcare resource utilization and costs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- CVS Healthspire™ Life Sciences Solution, Woonsocket, Rhode Island, USA.
- Cala Health, Inc., San Mateo, California, USA.
ORCID-Profile: Dingwei Dai, Chiahao Lu, Kathryn H Rosenbluth, Joaquim Fernandes
Zitieren
APA
Dai, D., Lu, C., Rosenbluth, K. H., & Fernandes, J. (2026). Clinical and Economic Outcomes of Transcutaneous Afferent Patterned Stimulation for Essential Tremor. Journal of Health Economics and Outcomes Research, 13(2). https://doi.org/10.36469/001c.170793
Vancouver
Dai D, Lu C, Rosenbluth KH, Fernandes J. Clinical and Economic Outcomes of Transcutaneous Afferent Patterned Stimulation for Essential Tremor. Journal of Health Economics and Outcomes Research. 2026;13(2). doi:10.36469/001c.170793
BibTeX
@article{Dai2026,
author = {Dai, Dingwei and Lu, Chiahao and Rosenbluth, Kathryn H and Fernandes, Joaquim},
title = {Clinical and Economic Outcomes of Transcutaneous Afferent Patterned Stimulation for Essential Tremor},
journal = {Journal of Health Economics and Outcomes Research},
year = {2026},
volume = {13},
number = {2},
doi = {10.36469/001c.170793}
}
EUVIMED